A Phase 4 interventional study of Verapamil in Radial Artery Spasm, sponsored by Mersin Medicalpark Hastanesi. Completed at 1 site in Turkey (Türkiye). Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.
Sponsored by Mersin Medicalpark Hastanesi · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Coronary angiography (CAG) is an invasive imaging method performed to determine the degree of coronary artery disease. Radial artery spasm (RAS) is one of the most common complications during coronary angiography performed via the transradial approach, causing patient discomfort or sometimes interrupting the procedure. There are many studies on RAS, and various pharmacoagents administered intravenously (intraarterial) to prevent RAS have been described. However, there is limited data in the literature regarding oral pharmacoagents that will prevent this complication. In our study, the preventive effect of Verapamil, given orally 2 hours before coronary angiography, on radial artery spasm will be investigated.
Transradial access (TRA) has emerged as the preferred modality for vascular access in coronary interventions worldwide, prompting growing interest in its potential applications across other interventional specialties, especially in neurovascular procedures. Radial artery spasm (RAS) remains the most common complication of TRA, often causing procedural difficulties, patient discomfort, and an increased risk of access site crossover. The incidence of radial artery spasm reported in the literature varies widely, with estimates ranging from 4% to over 51.3%, influenced by factors such as definitions, patient selection, and the operator's experience.
After puncturing the radial artery (Puncture-induced RAS) and inserting the sheath-but before administering intra-arterial spasmolytics-local discomfort and pain may trigger a sympathetic vasoconstrictive response, potentially leading to the onset of RAS.
A previous study has stated that preventing RAS is more effective than treating it after it has been established. In this context, we will conduct a randomized controlled trial to evaluate the efficacy of 120 mg of oral verapamil administered two hours before radial artery puncture in reducing the incidence of radial artery spasm (RAS)
123 studies on the registry are indexed under Spasm; 7 are open to participants now.
This study's enrollment of 150 is above the median of 80 across 104 interventional studies indexed under Spasm.
Browse Spasm studies →Mersin Medicalpark Hastanesi is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No other vasodilating drug such as nitrate will be given intravenously
Drug: Verapamil
Verapamil will be given orally at least 2 hours before angiography
Drug: Verapamil
Prevent
Number of Participants With Clinical Radial Artery Spasm (RAS)
Clinical RAS defined as presence of at least 2 of the following: (1) forearm pain ≥ 4/10, (2) pain during catheter manipulation, (3) catheter movement restriction, (4) pain during sheath removal, (5) difficulty in sheath removal.
Time frame: During the coronary angiography procedure (up to 2 hours from sheath insertion)
Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS)
Radial artery spasm (RAS) was defined as luminal narrowing of ≥50% as measured by ultrasonography at the access site.
Time frame: During the procedure, immediately after catheterization (within 2 hours)
Number of Participants With Procedural Success
Procedure success was defined as completing coronary angiography or PCI using the initial radial artery approach without requiring a switch to an alternative access site.
Time frame: During the procedure (from sheath insertion to procedure completion)
Mean Volume of Contrast Media Used (mL) (mL)
The volume of contrast media (in ml) used was recorded
Time frame: During the procedure (from sheath insertion to procedure completion)
Mean of the Dose Area Product (DAP)
The parameters collected for radiation exposure included the DAP
Time frame: During the procedure (from sheath insertion to procedure completion)
Mean of the Fluoroscopy Time
The parameters collected for radiation exposure included the fluoroscopy time (in minutes)
Time frame: During the procedure (from sheath insertion to procedure completion)
All consecutive patients undergoing transradial coronary angiography between June-November 2024 at Medicalpark Hospital (Mersin, Turkey) were included. Exclusion criteria were abnormal Allen test, absent radial pulse, prior radial access, hemodynamic instability, or contraindications to verapamil (e.g., severe AS, HR \<50, high-grade AV block, cardiogenic shock, EF \<35%).
| Milestone | Placebo | Verapamil |
|---|---|---|
| Started | 75 | 75 |
| Completed | 75 | 75 |
| Not completed | 0 | 0 |
Clinical RAS defined as presence of at least 2 of the following: (1) forearm pain ≥ 4/10, (2) pain during catheter manipulation, (3) catheter movement restriction, (4) pain during sheath removal, (5) difficulty in sheath removal.
| participants | Placebo | Verapamil |
|---|---|---|
| Number of Participants With Clinical Radial Artery Spasm (RAS) | 23 | 3 |
Radial artery spasm (RAS) was defined as luminal narrowing of ≥50% as measured by ultrasonography at the access site.
| participants | Placebo | Verapamil |
|---|---|---|
| Number of Participants With Ultrasonographically Confirmed Radial Artery Spasm (Ultrasonographic RAS) | 36 | 8 |
Procedure success was defined as completing coronary angiography or PCI using the initial radial artery approach without requiring a switch to an alternative access site.
| participants | Placebo | Verapamil |
|---|---|---|
| Number of Participants With Procedural Success | 75 | 75 |
The volume of contrast media (in ml) used was recorded
| Milliliters (mL) | Placebo | Verapamil |
|---|---|---|
| Mean Volume of Contrast Media Used (mL) (mL) | 133.8 ± 71.9 | 136.4 ± 78.3 |
The parameters collected for radiation exposure included the DAP
| Gy·cm2 | Placebo | Verapamil |
|---|---|---|
| Mean of the Dose Area Product (DAP) | 873.9 ± 732.3 | 878.8 ± 736.7 |
The parameters collected for radiation exposure included the fluoroscopy time (in minutes)
| minute | Placebo | Verapamil |
|---|---|---|
| Mean of the Fluoroscopy Time | 7.9 ± 7.3 | 6.9 ± 5.8 |
Collected over From procedure initiation through hospital discharge (average 1 day). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/75 (0%) | 0/75 (0%) | 0/75 (0%) |
| Verapamil | 0/75 (0%) | 0/75 (0%) | 0/75 (0%) |
All randomized participants were included in the analysis
| Age, Continuous(years) | Placebo | Verapamil | Total |
|---|---|---|---|
| Mean | 58.1 ± 12.1 | 59.4 ± 11.1 | 58.8 ± 11.6 |
| Sex: Female, Male(Participants) | Placebo | Verapamil | Total |
|---|---|---|---|
| Female | 23 | 26 | 49 |
| Male | 52 | 49 | 101 |
| Race and Ethnicity Not Collected(Participants) | Placebo | Verapamil | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Region of Enrollment(Participants) | Placebo | Verapamil | Total |
|---|---|---|---|
| Turkey | 75 | 75 | 150 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Nov 2024, 4 months.
Results were first posted in Oct 2025, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Verapamil
Mersin Medicalpark Hastanesi